ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.Immuno-oncology technology · 2026Article
- Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital.Virchows Archiv : an international journal of pathology · 2026Article
- 3D deep learning model to predict the recurrence of stage IA invasive lung adenocarcinoma after sub-lobar resection: a multicenter retrospective cohort study.Journal of imaging informatics in medicine · 2026Article
- Advancements in cancer biomarker discovery over fifteen years: diagnostics and prognostic approach in somatic cancer.Oncology reviews · 2026Review
- Therapeutic inhibition of RAS in non-small cell lung cancer.Frontiers in oncology · 2026Review
- The impact of spread through air spaces on intrapulmonary metastasis in lung cancer: a retrospective study of multiple primary lung adenocarcinomas with confirmed common origin based on histological classification alone and combined histological-molecular classification.Translational lung cancer research · 2025Article
- Distribution ofCancers · 2025Article
- CREPT promotes LUAD progression by enhancing the CDK9 and RNAPII assembly to promote ERK-driven gene transcription.Theranostics · 2025Article
- Prognostic impact of targetable driver alterations in resected early-stage lung cancer.Translational lung cancer research · 2024Article
- Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB).Translational lung cancer research · 2024Article
- Clinical impact ofTranslational lung cancer research · 2024Article
- The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer.OncoTargets and therapy · 2024Review
- Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring.Frontiers in oncology · 2024Article
- Article
- Prognostic Role ofDiagnostics (Basel, Switzerland) · 2023Review
- A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.Cancers · 2023Review
- Genomic mapping of metastatic organotropism in lung adenocarcinoma.Cancer cell · 2023Article
- [Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 2 institutions in 1 country.
Gregory D JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Raul CasoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Kay See TanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Brooke MastrogiacomoCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Francisco Sanchez-VegaCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Yuan LiuThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
James G ConnollyThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8742-103X
Yonina R Murciano-GoroffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9027-2891
Matthew J BottThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Daniela MolenaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1655-4473
Gaetano RoccoThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Valerie W RuschThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Smita SihagThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Sandra MisaleMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Alexander DrilonDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6806-9061
Kathryn C ArbourDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5951-8427
Gregory J RielyDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Neal RosenDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8307-654X
Piro LitoDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
Haiying ZhangDepartment of Pediatrics, Weill Cornell School of Medicine, New York, New York.ORCID 0000-0002-7158-2373
David C LydenDepartment of Pediatrics, Weill Cornell School of Medicine, New York, New York.ORCID 0000-0003-0193-4131
Charles M RudinDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5204-3465
David R JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. jonesd2@mskcc.org isbellj@mskcc.org lib1@mskcc.org.
Bob T LiDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York. jonesd2@mskcc.org isbellj@mskcc.org lib1@mskcc.org.ORCID 0000-0001-6661-8733
James M IsbellThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. jonesd2@mskcc.org isbellj@mskcc.org lib1@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MSURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7MDissecting KRAS oncoprotein signaling with small molecule inhibitorsR01CA230745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2018 to 2026
$3.8MBRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5MTargeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4MStudies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistanceR01CA230267 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LITO, PIRO · 2019 to 2023
$2.0MImage-guided irreversible electroporation directed CAR T-cell delivery to solid tumorsR01CA236615 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., SOLOMON, STEPHEN BARNETT · 2018 to 2022
$2.0MNCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA230267NCI NIH HHS R01 CA230745NCI NIH HHS R01 CA236615NCI NIH HHS R01 CA240472NCI NIH HHS T32 CA009501
Abstract
purposeEXPERIMENTAL
designPatients who underwent resection of stage I-III lung adenocarcinoma and next-generation sequencing (NGS) were evaluated. Exclusion criteria were receipt of induction therapy, incomplete resection, and low-quality NGS. Mutations were classified as
resultsIn total, 604 patients were included: 374
conclusions
Indexed as
AllelesAmino Acid SubstitutionMutationAdenocarcinoma of LungAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProto-Oncogene Proteins p21(ras)RecurrenceSurvival AnalysisTreatment OutcomeBiomarkers, TumorKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.